WO1995011668A1 - Gelatin capsule fill able to foam - Google Patents
Gelatin capsule fill able to foam Download PDFInfo
- Publication number
- WO1995011668A1 WO1995011668A1 PCT/GB1994/002380 GB9402380W WO9511668A1 WO 1995011668 A1 WO1995011668 A1 WO 1995011668A1 GB 9402380 W GB9402380 W GB 9402380W WO 9511668 A1 WO9511668 A1 WO 9511668A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbonate
- pharmaceutical product
- product according
- oil
- fill
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
Definitions
- This invention relates to pharmaceutical products and in particular to compositions for the treatment of reflux oesophagitis, gastritis or peptic ulceration.
- Reflux oesophagitis occurs when small amounts of gastric juice, food and/or bile acids pass into the lower part of the oesophagus and cause oesophageal inflammation accompanied by pain which may manifest itself in the form of heartburn.
- One approach to the problem of reflux oesophagitis comprises the administration of a preparation which on contact with gastric acid generates a carbonated gelatinous foam or raft which floats on the stomach contents. When reflux occurs it is this raft which precedes the stomach contents into the oesophagus thus protecting the mucosa from further irritation.
- a pharmaceutical product for the treatment of reflux oesophagitis, gastritis or peptic ulceration in the form of a chewable soft gelatin capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle; wherein on oral ingestion the gelatin capsule shell ruptures and the fill reacts with the acid contents of the stomach thereby producing a carbonated floating gelatinous raft of such rigidity that in the penetration test as hereinafter defined there is not complete penetration.
- the polymeric material is the sodium, potassium, ammonium, magnesium or calcium salt of alginic acid or the propylene glycol esters or mixtures thereof.
- rafts of improved strength are obtained if the composition includes a source of divalent calcium or trivalent aluminium ion which act as cross-linking agents.
- Suitable sources of calcium ions are those derived from the carbonate, lactate, chloride, gluconate, phosphate, hydrogen phosphate, sulphate, tartrate or citrate salts.
- Suitable sources of aluminium ions are those derived from the carbonate, lactate, glycinate or phosphate salts or from aluminium magnesium carbonate hydroxide, agaldrate, aluminium sodium carbonate hydroxide or aluminium sodium silicate. Conveniently the relative quantities by weight of the calcium salt or aluminium compound to the alginic acid or alginate calculated as ions are 4 to 120 Ca 2+ to 500 alginate " or 2 to 80 Al 3+ to 500 alginate" respectively.
- Suitable carbonate or bicarbonate salts are potassium carbonate or bicarbonate, sodium carbonate or bicarbonate, calcium carbonate, sodium glycine carbonate, magnesium carbonate or aluminium carbonate.
- the carbonate or bicarbonate salt is present in an amount so as to provide an adequate volume of gas (carbon dioxide) to float the gel produced when the polymeric material contacts the gastric acid in the stomach.
- gas carbon dioxide
- the relative quantities by weight of polymeric material to the carbonate or bicarbonate calculated as ions is 35 to 300 CO 3 2 " or HC0 3 ⁇ to 500 polymeric material.
- the rigidity and thickness of the carbonated raft formed on contact with the gastric acid will depend upon the ratio of carbonate or bicarbonate to the polymeric material and upon the grade of the polymeric material.
- Suitable oil-based liquid vehicles are natural oils such as soya bean oil, fractionated coconut oil, mineral oils, triacetin, ethyl oleate, hydrogenated natural oil and mixtures thereof.
- Suitable hydrophilic based liquid vehicles are polyethylene glycols (PEG's) particularly PEG 400 and PEG 600, glycofurol, polyglycerols, propylene glycol, Transcutol, polysorbate and propylene carbonate and mixtures thereof.
- the invention also includes a method of treating reflux oesophagitis, gastritis or peptic ulceration which comprises administration of an effective amount of a product which is capable of forming a floating gelatinous raft when contacted with the acid contents of the stomach said raft being of such rigidity that in the penetration test as hereinafter defined there is not complete penetration and said product being in the form of a chewable soft gelatin capsule with a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle.
- a fill comprising (a) polymeric material selected from alginic acid, alginates, pectin, xanthan, gellan, carageenan and mixtures thereof; (b) a carbonate or bicarbonate salt; (c) an oil-based or hydrophilic based liquid vehicle.
- the gelatin capsules may be simultaneously formed and filled using conventional methods and apparatus such as disclosed, for example, in an article by H. Seager in Pharmaceutical Technology September 1985.
- All the ingredients of the fill material including the liquid vehicle are mixed together, with heating if necessary, until the desired consistency for filling and the desired unifor ity is obtained.
- the encapsulation machine is suitably an R P Scherer encapsulation machine.
- a surfactant may be included in the fill.
- the polymeric materials will have a thickening effect upon the liquid fill.
- This thickening effect may be further increased if so desired by the inclusion of a thickening agent such as hydrogenated vegetable oils, glyceryl monostearate, glyceryl monopalmitate, beeswax (or other high melting point fat or wax) or a dispersed thickener such as colloidal silicon dioxide.
- a suitable thickening agent may be one or more high molecular weight PEG's.”
- the capsules will be suitably shaped and sized so as to be readily ingestible by a person following chewing.
- Example 1 The invention is illustrated by the following Examples: Example 1
- Capsules in a standard gelatin shell were prepared having the following fill:
- Capsules were prepared as in Example 1 except that the amount of calcium carbonate in the fill materials was increased to 100 mg.
- Example 3
- Capsules were prepared as in Example 1 having the following fill: Quantity/Capsule
- Example 4 were prepared as in Example 1 having the following fill:
- Example 5 1500 mg Example 5 Capsules were prepared as in Example 1 having the following fill:
- Capsules were prepared as in Example l having the following fill:
- the appropriate amount of product (equivalent to 6 doses of lg of polymeric material) was weighed and added to a 250ml tall-form beaker (height 120mm & diameter 60mm) previously weighed. A volume of 120ml of deionised water was added and the mixture homogenized for 5 minutes using the Silverson Model L4R ho ogenizer with a Turbular Unit 1" in diameter and a square hole high shear screen. The speed of the homogenizer was set at speed 4 / 5000-5200 rpm. In the case of Liquid Gaviscon and Algicon Mint, 120ml of the product was taken and added to a 250ml tall-form beaker.
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9407916A BR9407916A (pt) | 1993-10-29 | 1994-10-28 | Produto farmacêutico e processo para tratamento de esofagite de refluxo gastrite ou úlcera péptica |
EP94931124A EP0725626A1 (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
JP7512497A JPH09504286A (ja) | 1993-10-29 | 1994-10-28 | 発泡しうるゼラチンカプセル充填物 |
KR1019960702194A KR960705552A (ko) | 1993-10-29 | 1994-10-28 | 기포를 생성할 수 있는 젤라틴 캡슐 충전제(Gelatin capsule fill able to foam) |
AU80004/94A AU8000494A (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
NO961638A NO961638L (no) | 1993-10-29 | 1996-04-24 | Gelatinkapselfyllstoff som kan skumme |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9322314.7 | 1993-10-29 | ||
GB939322314A GB9322314D0 (en) | 1993-10-29 | 1993-10-29 | Foam generating capsules |
GB9411350.3 | 1994-06-07 | ||
GB9411350A GB2283171B (en) | 1993-10-29 | 1994-06-07 | Pharmaceutical products |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995011668A1 true WO1995011668A1 (en) | 1995-05-04 |
Family
ID=26303761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/002380 WO1995011668A1 (en) | 1993-10-29 | 1994-10-28 | Gelatin capsule fill able to foam |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0725626A1 (ja) |
JP (1) | JPH09504286A (ja) |
CN (1) | CN1133558A (ja) |
AU (1) | AU8000494A (ja) |
BR (1) | BR9407916A (ja) |
CA (1) | CA2174777A1 (ja) |
NO (1) | NO961638L (ja) |
NZ (1) | NZ274901A (ja) |
WO (1) | WO1995011668A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037300A1 (en) * | 2001-10-30 | 2003-05-08 | Astrazeneca Ab | Gastric raft composition |
GB2384986A (en) * | 2002-02-12 | 2003-08-13 | Reckitt Benckiser Healthcare | Solid compositions for the treatment of disorders of the upper gastrointestinal tract |
EP1951208A2 (en) * | 2005-10-26 | 2008-08-06 | Banner Pharmacaps Inc. | Lipophilic vehicle-based dual controlled release matrix system as capsule fill |
KR100919508B1 (ko) * | 2007-08-14 | 2009-09-28 | 강원대학교산학협력단 | 매트릭스에 칼슘 카보네이트를 함유한 알지네이트 입자 및그 제조방법 |
WO2010015800A1 (en) * | 2008-08-06 | 2010-02-11 | Reckitt Benckiser Healthcare (Uk) Limited | Chewable formulation comprising alginate, bicarbonate and carbonate |
EP2560732A2 (en) * | 2010-04-23 | 2013-02-27 | S-Biotek Holding ApS | A solid pharmaceutical composition for neutralizing stomach acid |
ITUB20156821A1 (it) * | 2015-12-09 | 2017-06-09 | Altergon Sa | CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE |
WO2019063891A1 (fr) | 2017-09-29 | 2019-04-04 | Laboratoires Arkopharma | Composition adaptée pour former un radeau gastrique gélifié |
US20190269717A1 (en) * | 2018-03-02 | 2019-09-05 | Pharagen Llc | Formulations for Treating Acid Reflux Comprising Sodium Alginate |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3959192B2 (ja) * | 1998-12-03 | 2007-08-15 | 株式会社大塚製薬工場 | 経管栄養食品 |
CN110353271B (zh) * | 2019-06-13 | 2022-07-22 | 陕西科技大学 | 一种抑制食道反流的特殊医学食品增稠组件及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2304354A1 (fr) * | 1975-03-17 | 1976-10-15 | Hoffmann La Roche | Nouvelles compositions pharmaceutiques a activite retardee |
FR2512676A1 (fr) * | 1981-09-14 | 1983-03-18 | Hoffmann La Roche | Composition a liberation commandee hydrodynamiquement equilibree |
FR2636532A1 (fr) * | 1988-09-20 | 1990-03-23 | Glaxo Group Ltd | Compositions pharmaceutiques |
-
1994
- 1994-10-28 AU AU80004/94A patent/AU8000494A/en not_active Abandoned
- 1994-10-28 WO PCT/GB1994/002380 patent/WO1995011668A1/en not_active Application Discontinuation
- 1994-10-28 JP JP7512497A patent/JPH09504286A/ja active Pending
- 1994-10-28 BR BR9407916A patent/BR9407916A/pt not_active Application Discontinuation
- 1994-10-28 EP EP94931124A patent/EP0725626A1/en not_active Withdrawn
- 1994-10-28 NZ NZ27490194A patent/NZ274901A/en unknown
- 1994-10-28 CN CN 94193934 patent/CN1133558A/zh active Pending
- 1994-10-28 CA CA 2174777 patent/CA2174777A1/en not_active Abandoned
-
1996
- 1996-04-24 NO NO961638A patent/NO961638L/no unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2304354A1 (fr) * | 1975-03-17 | 1976-10-15 | Hoffmann La Roche | Nouvelles compositions pharmaceutiques a activite retardee |
FR2512676A1 (fr) * | 1981-09-14 | 1983-03-18 | Hoffmann La Roche | Composition a liberation commandee hydrodynamiquement equilibree |
FR2636532A1 (fr) * | 1988-09-20 | 1990-03-23 | Glaxo Group Ltd | Compositions pharmaceutiques |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003037300A1 (en) * | 2001-10-30 | 2003-05-08 | Astrazeneca Ab | Gastric raft composition |
GB2384986A (en) * | 2002-02-12 | 2003-08-13 | Reckitt Benckiser Healthcare | Solid compositions for the treatment of disorders of the upper gastrointestinal tract |
WO2003068246A2 (en) * | 2002-02-12 | 2003-08-21 | Reckitt Benckiser Healthcare (Uk) Limited | Improvements in or relating to compositions |
WO2003068246A3 (en) * | 2002-02-12 | 2003-12-18 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions |
GB2384986B (en) * | 2002-02-12 | 2004-01-07 | Reckitt Benckiser Healthcare | Compositions for the treatment of disorders of the upper gastrointestinal tract |
AU2003205868B2 (en) * | 2002-02-12 | 2007-05-17 | Reckitt Benckiser Healthcare (Uk) Limited | Improvements in or relating to compositions |
KR100976071B1 (ko) * | 2002-02-12 | 2010-08-17 | 레킷트 벵키저 헬스케어(유케이)리미티드 | 조성물 내에서의 또는 조성물에 관련된 개선책 |
EP1951208A2 (en) * | 2005-10-26 | 2008-08-06 | Banner Pharmacaps Inc. | Lipophilic vehicle-based dual controlled release matrix system as capsule fill |
KR100919508B1 (ko) * | 2007-08-14 | 2009-09-28 | 강원대학교산학협력단 | 매트릭스에 칼슘 카보네이트를 함유한 알지네이트 입자 및그 제조방법 |
WO2010015800A1 (en) * | 2008-08-06 | 2010-02-11 | Reckitt Benckiser Healthcare (Uk) Limited | Chewable formulation comprising alginate, bicarbonate and carbonate |
EP2560732A2 (en) * | 2010-04-23 | 2013-02-27 | S-Biotek Holding ApS | A solid pharmaceutical composition for neutralizing stomach acid |
US9186409B2 (en) | 2010-04-23 | 2015-11-17 | S-Biotek Holidng Aps | Solid pharmaceutical composition for neutralizing stomach acid |
ITUB20156821A1 (it) * | 2015-12-09 | 2017-06-09 | Altergon Sa | CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE |
WO2017097612A1 (en) * | 2015-12-09 | 2017-06-15 | Altergon S.A. | SOFT GELATIN CAPSULES WITH pH-INDEPENDENT RELEASE |
RU2738933C2 (ru) * | 2015-12-09 | 2020-12-18 | Альтергон С.А. | Мягкие желатиновые капсулы с рН-независимым высвобождением |
US11304910B2 (en) | 2015-12-09 | 2022-04-19 | Altergon S.A. | Soft gelatin capsules with pH-independent release |
WO2019063891A1 (fr) | 2017-09-29 | 2019-04-04 | Laboratoires Arkopharma | Composition adaptée pour former un radeau gastrique gélifié |
FR3071728A1 (fr) * | 2017-09-29 | 2019-04-05 | Laboratoires Arkopharma | Composition adaptee pour former un radeau gastrique gelifie |
US20190269717A1 (en) * | 2018-03-02 | 2019-09-05 | Pharagen Llc | Formulations for Treating Acid Reflux Comprising Sodium Alginate |
US11110118B2 (en) * | 2018-03-02 | 2021-09-07 | Pharagen Llc | Formulations for treating acid reflux comprising sodium alginate |
US20210361697A1 (en) * | 2018-03-02 | 2021-11-25 | Pharagen Llc | Formulations for treating acid reflux comprising sodium alginate |
US11883427B2 (en) | 2018-03-02 | 2024-01-30 | Pharagen Llc | Formulations for treating acid reflux comprising sodium alginate |
US20240108647A1 (en) * | 2018-03-02 | 2024-04-04 | Pharagen Llc | Formulations for treating acid reflux comprising sodium alginate |
Also Published As
Publication number | Publication date |
---|---|
NO961638D0 (no) | 1996-04-24 |
NO961638L (no) | 1996-04-24 |
AU8000494A (en) | 1995-05-22 |
CN1133558A (zh) | 1996-10-16 |
EP0725626A1 (en) | 1996-08-14 |
JPH09504286A (ja) | 1997-04-28 |
BR9407916A (pt) | 1996-11-26 |
CA2174777A1 (en) | 1995-05-04 |
NZ274901A (en) | 1997-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1267090A (en) | Aerosol foam | |
CA1319106C (en) | Antacid composition | |
EP1978943B1 (en) | Chewable capsules | |
EP0725626A1 (en) | Gelatin capsule fill able to foam | |
CA1073358A (en) | Sustained release formulations | |
JPS6219054A (ja) | 水分不浸透性外層を有する層状チユ−インガム | |
US9452135B2 (en) | Gelling agent-based dosage form | |
GB2283171A (en) | Pharmaceutical product for treatment of reflux oesophagitis,gastritis or peptic ulceration | |
US5888540A (en) | Pharmaceutical products | |
EP0626168B1 (en) | Novel rafting antacid composition | |
AU692483B2 (en) | Gelatin capsule fill able to foam | |
US5173305A (en) | Composition for protection of oesogastroduodenal mucous membrane | |
AU614962C (en) | An antacid composition | |
JPH0150205B2 (ja) | ||
CA1116084A (en) | Negative contrast agent | |
DK166422B1 (da) | Antacidpraeparater | |
DK169122B1 (da) | Antacidpræparat | |
JP2005047809A (ja) | 内服用ゲル状組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94193934.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994931124 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 274901 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2174777 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1996 633804 Country of ref document: US Date of ref document: 19960423 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994931124 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994931124 Country of ref document: EP |